Abstract
Gastrointestinal stromal tumors (GISTs) have a rather wide morphologic spectrum. Here, we report a rare variant plexiform GIST in gastric antrum. Microscopically, the tumor showed plexiform or multinodular growth pattern, proliferation of spindle cells, presence of epithelioid cells, and abundant myxoid stroma with thin-walled blood vessels. The histologic features were similar to plexiform fibromyxoma. The typical characteristics of immunohistochemistry (positive for CD34, DOG-1 and CD117) confirmed the final diagnosis of GIST. This is a rare case of myxoid GIST characterized by a plexiform growth pattern.
Keywords: Gastrointestinal stromal tumors, plexiform fibromyxoma, c-KIT mutation
Background
Gastrointestinal stromal tumors are the most frequent mesenchymal tumors in gastrointestinal tract. Their behavior is driven by specific KIT- or PDFGRA-signaling [1]. Histologically, the tumor cells were comparatively monotypic with spindle cells (86%), epithelioid cells (5%), or mixed patterns (9%). Some histologic variants were recognized among the spindle tumor cells (palisaded-vacuolated, storiform, organ-like, perivascular collar-like, sclerosing and sarcomatous patterns). Such variants may also be recognized among epithelioid tumor cells (sclerosing, dyscohesive, diffuse hypercellular and sarcomatous patterns), which might have abundant myxoid stroma and hyaline degeneration [2]. However, myxoid GISTs which present with plexiform growth pattern were rare reported in older patients. In this paper, we report a case of this unique variant of GISTs and emphasize that it can be a potential pitfall for confusing with a plexiform fibermyxoma.
Case presentation
A 71-year-old Asian woman who presented with a one-year history of black stool. The patient was shock ten days ago, her blood pressure was 75/55 mmHg and hemoglobin was 50 g/l. At that time, the patient visited at a local hospital and received a gastroscope and an enteroscopy examination. The gastroscopy demonstrated a 4.5*4.0 cm tumor located at gastric angle, lesser curvature and anterior/posterior wall of the stomach, which was stiff by their surface texture, roughness, erosion and friable at the apex. The enteroscopy showed three polypous state upheavals at 30 cm-50 cm distance from the anal verge, the tumors were about 0.3*0.3 cm-0.6*0.6 cm at large. And 45 cm distance from the anal verge observed a 0.8*0.8 cm mucosa thickening. Then the patient went to our hospital from her locality and performed some other examination. Whole abdomen plain and enhancement CT computed tomography (CT) scanning showed a under stomach mucosa solid mass which was about 6*5 cm and located at the side of greater curvature of the gastric antrum. The CT value was about 22 Hu. Enhanced CT scanning displayed the lesion with uneven enhancement and the CT value was about 38 HU. No retroperitoneal lymph nodes, liver and peritoneum was seen abnormal. Upper gastrointestinal opacification showed filling defect at the gastric antrum and shallow stomach angle. The contour of greater and lesser gastric curvature were smooth. No abnormal was seen in other parts from esophagus to ileocecal junction. The patient had five-year history of hypertension and diabetes mellitus. And she had a history of adenomyosis at the age of 67 but without surgical procedures.She denied coronary heart disease, neurofibromatosis, pulmonary chondroma and paraganglioma. Serum levels of tumor markers included carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125), which were all within normal limits. The tumors were totally excised by a distal partial gastrectomy. The patient had no recurrence after 14 months of surgical treatment without imatinib treatment.
Materials and methods
The tissue was fixed in 10% buffered formalin and processed as routine for paraffin embedding, paraffin sectioning, and staining with hematoxylin-eosin. Immunohistochemical stains were performed by using the streptavidin-peroxidase procedure (Ultrasensitive, MaiXin Inc, Fuzhou, China) under the instructions of manufacturer. The antibodies were shown in Table 1. All series included positive and negative controls were included and evaluated through appropriate procedure.
Table 1.
Reagents and conditions used for immunohistochemistry
| Antibody | Clone | Dilution | Source | Results |
|---|---|---|---|---|
| CK (pan) | AE1/AE3 | Ready to use | Fuzhou Maixin Biology, Fouzhou, China | - |
| Vimentin | SP20 | Ready to use | Fuzhou Maixin Biology, Fouzhou, China | + |
| CD117 | A4502 | 1:100 | Dako, Carpinteria, CA, USA | + |
| DOG1 | K9 | 1:100 | Dako, Carpinteria, CA, USA | + |
| CD34 | QBEnd/10 | 1:100 | Dako, Carpinteria, CA, USA | + |
| SDHB | CL0349 | 1:100 | Sigma-Aldrich, MO, USA | - |
| Actin (SMA) | RB-9010 | 1:100 | Dako, Carpinteria, CA, USA | - |
| desmin | D33 | 1:100 | Dako, Carpinteria, CA, USA | - |
| S-100 | 4C4.9 | 1:100 | Dako, Carpinteria, CA, USA | - |
| β-Catenin | DO-7 | 1:75 | Dako, Carpinteria, CA, USA | nucleus- |
| Ki67 | MIB-1, | Ready to Use | Fuzhou Maixin Biology, Fouzhou, China | 2%+ |
| CD10 | MX002 | Ready to Use | Fuzhou Maixin Biology, Fouzhou, China | - |
| CgA | SP12 | Ready to Use | Fuzhou Maixin Biology, Fouzhou, China | - |
| Syn | RM-9111 | 1:75 | Fuzhou Maixin Biology, Fouzhou, China | - |
| CD68 | KP1 | Ready to Use | Fuzhou Maixin Biology, Fouzhou, China | - |
| NF1 | 31G7 | 1:50 | Invitrogen, Inc., Carlsbad, CA, USA | - |
| ALK | ALK-1 | 1:100 | Dako, Carpinteria, CA, USA | - |
Abbreviations: CK-Pan, pan-cytokeratin; SDHB, succinate dehydrogenase B; CgA, chromogranin A; Syn, synaptophysin; NF1, neuronespecific enolase 1; ALK, anaplastic lymphoma receptor tyrosine kinase.
Pathologic findings
Histologically, at low magnification, the tumor was located in the submucosa without intruding into the mucosa (Figure 1A) and exhibited multiple myxoid nodules (Figure 1B). The nodules were in the remaining gastric muscular propria and had a pushing border even extending to the layer of the muscularis (Figure 1C). The plexiform nodules have three main characterizes included spindle cells, mucinous extracellular matrix and thin blood vessels (Figure 1D). The spindle cells were similar to myofibroblastic cells. They had indistinct cytoplasm and cellular borders with the presence of nucleoli and occasional intracytoplasmic perinuclear vacuoles. In some regions, the nodules were composed of scattered clusters of epithelioid cells which seemed consistent with epithelioid GIST (Figure 1E), some signet ring cells were found (Figure 1F). Nuclear atypia was mild in nuclear enlargement, and the tumor cells had a low mitotic activity (<1 mitoses/50 high-power fields). No coagulative necrosis, perineural invasion, or vascular invasion were found.
Figure 1.

Hematoxylin and eosin staining. A. Low-power view demonstrates a multilobulated mass within the muscularis propria (original magnification ×25). B. The tumor exhibits a plexiform growth pattern with entrapment of smooth muscle fibers at the periphery (original magnification ×12.5). C. The nodules infiltrative to the muscularis (original magnification ×100). D. Tumor nodules are composed of a rich myxoid stroma, uniform spindle cells and delicate capillary (original magnification ×100). E. The tumor cells exhibited scattered clusters of epithelioid cells (hematoxylin-eosin, original magnification ×100). F. Some cells presented with signet ring cells (original magnification ×200).
Immunohistochemical findings
The spindle cells and epithelioid cells were typically immunoreactive for vimentin, CD34 (Figure 2A), c-KIT (Figure 2B) and Dog1 (Figure 2C), but negative for SDHB (Figure 2D), Actin (SMA), Desmin, S-100, Cytokeratin (pan), CD10, NF1, CD68, ALK and Neuroendocrine markers (CgA and Syn). No nuclear β-Catenin positivity could be found. The Ki-67 labeling index was about 2%.
Figure 2.

Immunohistochemical analysis. A. Immunohistochemical staining for CD34 showing strong positivity in the tumor cells and vascular endothelial cells (original magnification ×100). B. Tumor cells were diffusely positive for CD117 (c-Kit) protein (original magnification ×100). C. DOG1 immunohistochemistry shows strong cytoplasmic staining in the tumor cells (original magnification ×100). D. The tumor cells were negative for SDHB (original magnification ×100).
Discussion
GISTs, a subgroup of gastrointestinal mesenchymal neoplasms, may originate from interstitial cells of Cajal (ICC) or their stem cell-like precursors [3]. High mitosis count, large tumor size, non-gastric location, rupture, and male sex were independent adverse prognostic risks of patients with operable GISTs [4]. GISTs have a broad spectrum of morphological variants. There have been several literatures reporting that histologic subtypes were important prognostic features [5]. Patients of GISTs with epithelioid or mixed histology had a higher risk of 5-year recurrence, compared to those with spindle-cells histology [6]. Hou YY [7] showed that morphologic features of perivascular growth pattern to be associated with malignancy. Several recent results suggest that myxoid epithelioid GISTs are closely correlated with the platelet-derived growth factor receptor alpha (PDGFRA) gene mutation [8]. In this case, GISTs were composed of the mixed spindle and epithelioid cells within myxoid matrix and exhibited plexiform growth pattern. It was categorized by intermediate-risk according to the modified National Institutes of Health (NIH) consensus classification system. The patient had no recurrence after 14 months of surgical treatment, suggesting this unusual morphologic variation may having no close correlation with tumor malignant biological behavior.
Plexiform growth patterns have been described as a particular structure variants in various mesenchymal tumors, including neurofibromas [9], schwannomas [10], plexiform fibrous histiocytomas [11], plexiform fibermyxomas [12] and so on. Plexiform fibromyxomas are new gastric mesenchymal tumors recently described in the WHO classification of tumors in the digestive system [13]. The clinical manifestations of plexiform fibromyxomas are similar with the GISTs, which are apparently specific location in the gastric antrum or the duodenal bulb. The histology indicated a plexiform growth pattern composed of spindle cells, fine small vessels and the myxoid matrix [12]. The tumor cells had limited atypia and mitotic activity lower than 5/50 high-power fields. Plexiform fibromyxomas were always positive for vimentin, actin (SMA) and variably for CD10, and were always negative for CD34, c-KIT, DOG1, Desmin, and S-100 protein, without c-KIT or PDGFR-a mutations were present [14]. This current case was presented with submucosal of gastric antrum, histological characteristics similar to plexiform fibromyxoma. However, in immunophenotype, the positivity for c-KIT, DOG1, CD34 plus negativity for actin (SMA) and CD10 help excluding plexiform fibromyxomas. Immunohistochemical stains are also helpful in differentiating plexiform GISTs from other myxoid and fibromyxoid gastric neoplasms, such as plexiform neurofibromas (S-100 negative), plexiform schwannomas (S-100 negative), plexiform fibrohistiocytic tumors (CD68 negative), inflammatory myofibroblastic tumors (actin (SMA) and ALK negative). The lack of a prominent mixed inflammatory components distinguished our case from inflammatory fibroid polyps.
Plexiform growth pattern has been reported in some succinate dehydrogenase (SDH)--deficient GISTs. SDH-deficient GISTs often occur exclusively in the stomach, show predilection to young females, and have rarely been diagnosed in older patients [15]. In this case, immunohistochemical staining showed SDHB-negative expression. In addition, genetic mutation analysis exons 9, 11, 13, 17 of the C-Kit gene and exons 12, 18 of the PDGFRA gene did not detect any type of mutation in the present case (data not show). These results strongly support a diagnosis of SDH-deficient GIST.
Conclusions
In summary, this report emphasizes that plexiform growth pattern is an unusual variable pathological features of myxoid GISTs and it is a challenging to make a diagnosis by histologic features. Pathologists should be aware of this phenomenon, avoiding misdiagnosing the disease as plexiform fibromyxomas.
Acknowledgements
This study was supported by Natural Science Foundation of Liaoning Province of China (No: L2015598, No: L2015585). We wish to thank the patient and her husband for providing a detailed disease history and agreeing our case report. Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Disclosure of conflict of interest
None.
References
- 1.Corless CL. Gastrointestinal stromal tumors: what do we know now? Mod Pathol. 2014;27(Suppl 1):S1–16. doi: 10.1038/modpathol.2013.173. [DOI] [PubMed] [Google Scholar]
- 2.Hemmings C, Yip D. The changing face of GIST: implications for pathologists. Pathology. 2014;46:141–8. doi: 10.1097/PAT.0000000000000047. [DOI] [PubMed] [Google Scholar]
- 3.Min KW, Leabu M. Interstitial cells of Cajal (ICC) and gastrointestinal stromal tumor (GIST): facts, speculations, and myths. J Cell Mol Med. 2006;10:995–1013. doi: 10.1111/j.1582-4934.2006.tb00541.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi C, Bordoni A, Magnusson MK, Linke Z, Sufliarsky J, Federico M, Jonasson JG, Dei Tos AP, Rutkowski P. Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265–74. doi: 10.1016/S1470-2045(11)70299-6. [DOI] [PubMed] [Google Scholar]
- 5.Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, Fletcher JA. Prognostic Value of KIT Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors. J. Clin. Oncol. 2002;20:3898–905. doi: 10.1200/JCO.2002.03.095. [DOI] [PubMed] [Google Scholar]
- 6.Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30:477–89. doi: 10.1097/00000478-200604000-00008. [DOI] [PubMed] [Google Scholar]
- 7.Hou YY, Lu SH, Zhou Y, Xu JF, Ji Y, Hou J, Qi WD, Shi Y, Tan YS, Zhu XZ. Predictive values of clinical and pathological parameters for malignancy of gastrointestinal stromal tumors. Histol Histopathol. 2009;24:737–47. doi: 10.14670/HH-24.737. [DOI] [PubMed] [Google Scholar]
- 8.Sakurai S, Hasegawa T, Sakuma Y, Takazawa Y, Motegi A, Nakajima T, Saito K, Fukayama M, Shimoda T. Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene. Hum Pathol. 2004;35:1223–30. doi: 10.1016/j.humpath.2004.07.008. [DOI] [PubMed] [Google Scholar]
- 9.Dagalakis U, Lodish M, Dombi E, Sinaii N, Sabo J, Baldwin A, Steinberg SM, Stratakis CA, Widemann BC. Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. J Pediatr. 2014;164:620–4. doi: 10.1016/j.jpeds.2013.10.081. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Berg JC, Scheithauer BW, Spinner RJ, Allen CM, Koutlas IG. Plexiform schwannoma: a clinicopathologic overview with emphasis on the head and neck region. Hum Pathol. 2008;39:633–40. doi: 10.1016/j.humpath.2007.10.029. [DOI] [PubMed] [Google Scholar]
- 11.Lynnhtun K, Achan A, Shingde M, Chou S, Howle JR, Sharma R. Plexiform fibrohistiocytic tumour: morphological changes and challenges in assessment of recurrent and metastatic lesions. Histopathology. 2012;60:1156–8. doi: 10.1111/j.1365-2559.2011.04173.x. [DOI] [PubMed] [Google Scholar]
- 12.Lee PW, Yau DT, Lau PP, Chan JK. Plexiform fibromyxoma (plexiform angiomyxoid myofibroblastic tumor) of stomach: an unusual presentation as a fistulating abscess. Int J Surg Pathol. 2014;22:286–90. doi: 10.1177/1066896913492198. [DOI] [PubMed] [Google Scholar]
- 13.Bosman FT, Carneiro F, Hruban RH, Theise ND World Health Organization. World Health Organization Classification of Tumours. 4th edition. IARC press; 2010. WHO Classification of digestive tumors; pp. 74–76. [Google Scholar]
- 14.Miettinen M, Makhlouf HR, Sobin LH, Lasota J. Plexiform fibromyxoma: a distinctive benign gastric antral neoplasm not to be confused with a myxoid GIST. Am J Surg Pathol. 2009;33:1624–32. doi: 10.1097/PAS.0b013e3181ae666a. [DOI] [PubMed] [Google Scholar]
- 15.Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011;35:1712–1721. doi: 10.1097/PAS.0b013e3182260752. [DOI] [PMC free article] [PubMed] [Google Scholar]
